Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine

Psychoneuroendocrinology

Volumn 31, Issue 5, 2006, Pages 577-588

  Kinon, Bruce J ^a   Ahl, Jonna ^a   Liu Seifert, Hong ^a   Maguire, Gerald A ^b  

^a ELI LILLY AND COMPANY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Hyperprolactinemia; Olanzapine; Reproductive hormones; Risperidone; Sexual dysfunction

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; FLUPHENAZINE; HALOPERIDOL; LOW DENSITY LIPOPROTEIN; MESORIDAZINE; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PROLACTIN; RISPERIDONE; TESTOSTERONE; THIORIDAZINE; TIOTIXENE;

ADULT; AGED; AKATHISIA; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DYSKINESIA; DYSPNEA; EOSINOPHIL COUNT; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GALACTORRHEA; GENITAL SYSTEM; GYNECOMASTIA; HALLUCINATION; HUMAN; HYPERPROLACTINEMIA; INSOMNIA; INVOLUNTARY MOVEMENT; MAJOR CLINICAL STUDY; MALE; MENSTRUAL CYCLE; MENSTRUATION; MENSTRUATION DISORDER; PARKINSONISM; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; RHINITIS; SCHIZOPHRENIA; SCHIZOPHRENIC REACTION; SEXUAL DYSFUNCTION; SEXUALITY; SIDE EFFECT; SOMNOLENCE; STATISTICAL SIGNIFICANCE; TESTOSTERONE BLOOD LEVEL;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BODY WEIGHT; ESTRADIOL; FEMALE; GALACTORRHEA; GYNECOMASTIA; HUMANS; MALE; MENSTRUAL CYCLE; PREMENOPAUSE; PROLACTIN; REPRODUCTION; RISPERIDONE; SCHIZOPHRENIA; SEX CHARACTERISTICS; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; TESTOSTERONE;

EID: 33646204615     PISSN: 03064530     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2005.12.006     Document Type: Article

References (44)

1. Barnes T.R. A rating scale for drug-induced akathisia. Br. J. Psychiat. 154 (1989) 672-676
2. Ben-Jonathan N., and Hnasko R. Dopamine as a prolactin inhibitor. Endocrinol. Rev. 22 6 (2001) 724-763
3. Boyd A. Bromocriptine and psychosis: a literature review. Psychiatry Q. 66 1 (1995) 87-95
4. Buvat J., Lemaire A., Buvat-Herbaut M., Fourlinnie J.C., Racadot A., and Fossati P. Hyperprolactinemia and sexual function in men. Horm. Res. 22 3 (1985) 196-203
5. Canuso C.M., Goldstein J.M., Wojcik J., Dawson R., Brandman D., Klibanski A., Schildkraut J.J., and Green A.I. Antipsychotic medication, prolactin elevation, and ovarian function in women with schizophrenia and schizoaffective disorder. Psychiatry Res. 111 1 (2002) 11-20
6. Compton M.T., and Miller A.H. Antipsychotic-associated hyperprolactinemia and sexual dysfunction. Psychopharmacol. Bull. 36 1 (2002) 143-164
7. Crawford A.M., Beasley Jr. C.M., and Tollefson G.D. The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. Schizophr. Res. 26 1 (1997) 41-54
8. David S.R., Taylor C.C., Kinon B.J., and Breier A. The effect of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clin. Ther. 22 9 (2000) 1085-1096
9. Dickson R.A., and Glazer W.M. Neuroleptic-induced hyperprolactinemia. Schizophr. Res. Suppl. (1999) S75-S86
10. Dickson R.A., Dalby J.T., Williams R., and Edwards A.L. Risperidone-induced prolactin elevations in premenopausal women with schizophrenia. Am. J. Psychiatry 152 7 (1995) 1102-1103
11. Folstein M.F., Folstein S.E., and McHugh P.R. Mini mental state: a practical method for grading the cognitive state of patients for the clinician. J. Psychiatry Res. 12 (1975) 189-198
12. Fujimoto V.Y., Clifton D.K., Cohen N.L., and Soules M.R. Variability of serum prolactin and progesterone levels in normal women: the relevance of single hormone measurements in the clinical setting. Obstet. Gynecol. 76 1 (1990) 71-78
13. Gazzola L.R., and Opler L.A. Return of menstruation after switching from risperidone to olanzapine. J. Clin. Psychopharmacol. 18 6 (1998) 486-487
14. Ghadirian A.M., Chouinard G., and Annable L. Sexual dysfunction and plasma prolactin levels in neuroleptic-treated schizophrenic outpatients. J. Nerv. Ment. Disord. 170 (1982) 463-467
15. Goff D.C., Posever T., Herz L., Simmons J., Kletti N., Lapierre K., Wilner K.D., Law C.G., and Ko G.N. An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder. J. Clin. Psychiatry 18 4 (1998) 296-304
16. In: Guy W. (Ed). ECDEU Assessment Manual for Psychopharmacology: Publication Adm 76-338 (1976), US Department of Health, Education, and Welfare, Washington, DC 534-537
17. Halbreich U., Rojanzky N., Palter S., Hreshchyshyn M., Kreeger J., Bakhai Y., and Rosan R. Decreased bone mineral density in medicated psychiatric patients. Psychosom. Med. 57 (1995) 485-491
18. Halbreich U., Kinon B.J., Gilmore J.A., and Kahn S.L. Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects. Psychoneuroendocrinology 28 (2003) 53-67
19. Kane J.M., Carson W.H., Saha A.R., McQuade R.D., Ingenito G.G., Zimbroff D.L., and Ali M.W. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J. Clin. Psychiatry 63 (2002) 763-771
20. Kapur S., and Seeman P. Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotics action. Am. J. Psychiatry 158 (2001) 360-369
21. Kapur S., Langlois X., Vinken P., Megens A.A., De Coster R., and Andrews J.S. The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis in rats. J. Pharmacol. Exp. Ther. 302 3 (2002) 1129-1134
22. Kay S.R., Fisbein A., and Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 13 2 (1987) 261-276
23. Kearns A.E., Goff D.C., Hayden D.L., and Daniel G.H. Risperidone-associated hyperprolactinemia. Endocr. Pract. 6 6 (2000) 425-429
24. Kim K.-S., Pae C.-U., Chae J.-H., Bahk W.-M., Jun T.-Y., Kim D.-J., and Dickson R.A. Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone. J. Clin. Psychiatry 63 5 (2002) 408-413
25. Kinon B.J., Basson B.R., Gilmore J.A., Malcolm S., and Stauffer V.L. Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine. J. Clin. Psychiatry 61 (2000) 833-840
26. Kinon B.J., Gilmore J.A., Liu H., and Halbreich U. Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone. Psychoneuroendocrinology 28 (2003) 55-68
27. Kleinberg D.L., Davis J.M., de Coster R., Van Baelen B., and Brecher M. Prolactin levels and adverse events in patients treated with risperidone. J. Clin. Psychopharmacol. 19 (1999) 57-61
28. Knegtering H., van der Moolen A.E.G.M., Castelein S., Kluiter H., and van den Bosch R.J. What are the effects of antipsychotics on sexual dysfunctions and endocrine functioning?. Psychoneuroendocrinology 28 (2003) 109-123
29. Meltzer H.Y., and Fang V.S. The effect of neuroleptics on serum prolactin in schizophrenic patients. Arch. Gen. Psychiatry 33 3 (1976) 279-286
30. Meltzer H.Y., Goode D.J., Schyve P.M., Young M., and Fang V.S. Effect of clozapine on human serum prolactin levels. Am. J. Psychiatry 136 12 (1979) 1550-1555
31. Meltzer H.Y., Busch D.A., and Fang V.S. Serum neuroleptic and prolactin levels in schizophrenic patients and clinical response. Psychiatry Res. 41 (1983) 249-255
32. Overall J.E., and Gorham D.E. The brief psychiatric rating scale. Psychol. Rep. 10 (1962) 799-812
33. Perkins D.O. Predictors of noncompliance in patients with schizophrenia. J. Clin. Psychiatry 63 12 (2002) 1121-1128
34. Peuskens P., Sienaert P., and DeHert M. Sexual dysfunction: the unspoken side effect of antipsychotics. Eur. Psychiatry 13 Suppl. (1998) 23S-30S
35. Rinieris P., Hatzimanolis J., Markianos M., and Stefanis C. Effects of treatment with various dose of haloperidol on the pituitary-gonadal azis in male schizophrenic patients. Neuropsychobiology 22 (1989) 146-149
36. Simpson G.M., and Angus J.W.S. A rating scale for extrapyramidal side effects. Acta Psychiatr. Scand. 212 Suppl. (1970) 11-19
37. Small J.G., Hirsch S.R., Arvanitis L.A., Miller B.J., and Link C.G. Quetiapine in patients with schizophrenia: a high- and low-dose double-blind comparison with placebo. Arch. Gen. Psychiatry 54 6 (1997) 549-557
38. Smith S., Wheeler M.J., Murray R., and O'Keane V. The effects of antipsychotic-associated hyperprolactinemia on the hypothalamic-pituitary-gonadal axis. J. Clin. Psychopharmacol. 22 2 (2002) 109-114
39. Tollefson G.D., Beasley Jr. C.M., Tran P.V., Street J.S., Krueger J.A., Tamura R.N., Graffeo K.A., and Thieme M.E. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am. J. Psychiatry 154 (1997) 457-465
40. Turrone P., Kapur S., Seeman M.V., and Flint A.J. Elevation of prolactin levels by atypical antipsychotics. Am. J. Psychiatry 159 1 (2002) 133-135
41. Volavka J., Czobor P., Cooper T.B., Sheitman B., Lindenmayer J.-P., Citrome L., McEvoy J.P., and Lieberman J.A. Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. J. Clin. Psychiatry 65 1 (2004) 57-61
42. Walker S.E., Allen S.H., Hoffman R.W., and McMurray R.W. Prolactin: a stimulator of disease activity in systemic lupus erythematosus. Lupus 4 1 (1995) 3-9
43. Welsch C.W., and Nagasawa H. Prolactin and murine mammary tumorigenesis: a review. Cancer Res. 37 (1977) 951-963
44. Wilson C.A. Pharmacological targets for the control of male and female sexual behavior. In: Riley A.J., Peet M., and Wilson C.A. (Eds). Sexual Pharmacology (1993), Oxford Medical Publications, Oxford 1-58